Pancreatic Cancer Research

ResearcherTel Aviv UniversityActive in the last 2 years

Anke Reinacher‐Schick

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7838-6877; OpenAlex author ID A5032081163, A5112168986. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
102
Papers, trials and grants by year

2012: 1 paper · 2013: 1 paper · 2014: none · 2015: none · 2016: none · 2017: none · 2018: 3 papers · 2019: 5 papers · 2020: none · 2021: 2 papers · 2022: 2 papers · 2023: 3 papers · 2024: 6 papers · 2025: 3 papers · 2026: 1 paper

Papers 27

  1. Erratum: Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomi… Co-author DOI 10.1200/jco-25-03004↗
  2. PANTAX: a phase Ib clinical trial of the efflux pump inhibitor SCO-101 in combination with gemcitabine and nab-paclitaxel in non-resectable or metastatic pancr… First author DOI 10.1007/s10637-025-01526-7↗
  3. Molecular Tissue Profiling in a Clinically Selected Pancreatic Cancer Cohort. Last author DOI 10.1159/000543997↗
  4. Benefit of Chemoradiotherapy Versus Chemotherapy After Induction Therapy for Conversion of Unresectable Into Resectable Pancreatic Cancer: The Randomized CONKO… Co-author DOI 10.1200/jco-24-01502↗
  5. Trametinib in combination with hydroxychloroquine or palbociclib in advanced metastatic pancreatic cancer: data from a retrospective, multicentric cohort (AIO … Co-author DOI 10.1007/s00432-024-05954-5↗
  6. Three-month life expectancy as inclusion criterion for clinical trials in advanced pancreatic cancer: is it really a valid tool for patient selection? Co-author DOI 10.1007/s12094-023-03323-1↗
  7. Changes over time in the course of advanced pancreatic cancer treatment with systemic chemotherapy: a pooled analysis of five clinical trials from two decades … Co-author DOI 10.1016/j.esmoop.2024.102944↗
  8. Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pan… Co-author DOI 10.1016/s2468-1253(24)00197-3↗
  9. Prioritization and Resource Allocation in the Context of the COVID-19 Pandemic: Recommendations for Colorectal and Pancreatic Cancer in Germany. Co-author DOI 10.1159/000538171↗
  10. Impact of preoperative chemotherapy on surgical results in 139 patients with locally advanced pancreatic cancer. Co-author DOI 10.21037/hbsn-23-426↗
  11. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)-a randomized phase II trial of the AIO pancreatic canc… Co-author DOI 10.1016/j.annonc.2022.09.161↗
  12. 68Ga-Labeled Fibroblast Activation Protein Inhibitor (68Ga-FAPI) PET for Pancreatic Adenocarcinoma: Data from the 68Ga-FAPI PET Observational Trial. Co-author DOI 10.2967/jnumed.122.264827↗
  13. Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pan… Co-author DOI 10.3390/curroncol30060436↗
  14. Platinum-Based Chemotherapy in Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma: Summary of Evidence and Application in Clinical Practice. Co-author DOI 10.1159/000527692↗
  15. Overall Survival Results From the POLO Trial: A Phase III Study of Active Maintenance Olaparib Versus Placebo for Germline BRCA-Mutated Metastatic Pancreatic C… Co-author DOI 10.1200/jco.21.01604↗
  16. R0 resection following chemo (radio)therapy improves survival of primary inoperable pancreatic cancer patients. Interim results of the German randomized CONKO-… Co-author DOI 10.1007/s00066-020-01680-2↗
  17. Afatinib plus gemcitabine versus gemcitabine alone as first-line treatment of metastatic pancreatic cancer: The randomised, open-label phase II ACCEPT study of… Co-author DOI 10.1016/j.ejca.2020.12.029↗
  18. Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. Co-author DOI 10.1056/nejmoa1903387↗
  19. Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib. Co-author DOI 10.1093/annonc/mdz406↗
  20. Pathologic Complete Response of Pancreatic Cancer following Neoadjuvant FOLFIRINOX Treatment in Hepatic Metastasized Pancreatic Cancer. Co-author DOI 10.1159/000497827↗
  21. Consensus in determining the resectability of locally progressed pancreatic ductal adenocarcinoma - results of the Conko-007 multicenter trial. Co-author DOI 10.1186/s12885-019-6148-5↗
  22. A Blood-Based Multi Marker Assay Supports the Differential Diagnosis of Early-Stage Pancreatic Cancer. Co-author DOI 10.7150/thno.29247↗
  23. Efficacy of gemcitabine plus erlotinib in rash-positive patients with metastatic pancreatic cancer selected according to eligibility for FOLFIRINOX: A prospect… Co-author DOI 10.1016/j.ejca.2018.02.008↗
  24. Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer - the NEONAX trial (AIO-PAK-0313), a prospective, r… Co-author DOI 10.1186/s12885-018-5183-y↗
  25. FOLFIRINOX treatment leading to pathologic complete response of a locally advanced pancreatic cancer. Co-author DOI 10.21037/jgo.2018.01.07↗
  26. [S3-guideline exocrine pancreatic cancer]. Co-author DOI 10.1055/s-0033-1356220↗
  27. Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancer. Co-author DOI 10.1038/bjc.2012.18↗

Closest collaborators

The 25 strongest of 102 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Waldemar H. Uhl · 11 shared papers, 2018–2026 · strength 1.42
  2. Stefan Hubert Boeck · 10 shared papers, 2012–2026 · strength 1.32
  3. Andrea Tannapfel · 8 shared papers, 2018–2026 · strength 1.32
  4. Dirk Waldschmidt · 5 shared papers, 2021–2026 · strength 0.83
  5. Thomas Jens Ettrich · 7 shared papers, 2018–2025 · strength 0.83
  6. Volker Heinemann · 7 shared papers, 2012–2024 · strength 0.82
  7. Klara Dorman · 5 shared papers, 2023–2024 · strength 0.78
  8. Michael B. Ghadimi · 6 shared papers, 2019–2026 · strength 0.77
  9. Uwe A. Wittel · 6 shared papers, 2018–2026 · strength 0.76
  10. Helmut Oettle · 5 shared papers, 2019–2026 · strength 0.74
  11. Jens Thomas Siveke · 5 shared papers, 2018–2024 · strength 0.68
  12. Christoph Benedikt Westphalen · 5 shared papers, 2018–2024 · strength 0.64
  13. Michael Haas · 5 shared papers, 2018–2024 · strength 0.63
  14. Dorota Łubgan · 4 shared papers, 2019–2026 · strength 0.58
  15. Henriette Golcher · 4 shared papers, 2019–2026 · strength 0.58
  16. Robert Grützmann · 4 shared papers, 2019–2026 · strength 0.58
  17. Thomas Theodor Werner Seufferlein · 5 shared papers, 2018–2023 · strength 0.54
  18. Hana Algül · 6 shared papers, 2018–2023 · strength 0.52
  19. Sabine Semrau · 3 shared papers, 2021–2026 · strength 0.50
  20. Rainer Fietkau · 3 shared papers, 2021–2026 · strength 0.50
  21. Volker Kunzmann · 4 shared papers, 2018–2024 · strength 0.49
  22. Julia V. Mayerle · 3 shared papers, 2023–2024 · strength 0.47
  23. Dirk Arnold · 4 shared papers, 2019–2022 · strength 0.45
  24. Michael Geißler · 5 shared papers, 2012–2024 · strength 0.45
  25. Stefanie Hegenberg · 2 shared papers, 2024–2025 · strength 0.43

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.